Table S1. All of the patients were male, smokers, and SCLC.
| ID | Gender | Age | Smoking history | Tumor type | T | N | M | Stagea | Stageb | Treatment | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LU-01-1120 | Male | 67 | 1 | SCLC | 4 | 0 | 1 | 4 | ED | EP | SD |
| LU-01-1142 | Male | 68 | 1 | SCLC | 3 | 2 | 0 | 3 | LD | EC | PR |
| LU-01-1147 | Male | 54 | 1 | SCLC | 4 | 1 | 1 | 4 | ED | EC | PD |
| LU-01-1192 | Male | 66 | 1 | SCLC | 2 | 3 | 1 | 4 | ED | EC | PR |
| TYQ | Male | 69 | 1 | SCLC | 4 | 3 | 1 | 4 | ED | EC | SD |
| PXG | Male | 63 | 1 | SCLC | 4 | 3 | 0 | 3 | LD | EC | PR |
a, TNM stage, tumor node metastasis; b, Veterans Administration Lung Study Group (VALSG), limited disease and extensive disease. SCLC, small cell lung cancer; ED, extensive disease; EP, etoposide plus cisplatin; LD, limited disease; EC, etoposide plus carboplatin; PR, partial response. SD, stable disease; PD, progressive disease.